|Videos|October 1, 2016

Shared Decision-Making in Hematologic Malignancies

In this video we discuss the goals of shared-decision making in hematologic malignancies and touch upon different scenarios where its use may be appropriate.

In this video, Thomas W. LeBlanc, MD, MA, of the Duke Cancer Institute in Durham, North Carolina, discusses the goals of shared-decision making when treating patients with hematologic malignancies and touches upon different scenarios where its use may be appropriate.

Dr. LeBlanc gave a presentation on this topic at the 11^th Annual National Comprehensive Cancer Network (NCCN) Hematologic Malignancies Congress, held September 1–October 1 in New York.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Shared Decision-Making in Hematologic Malignancies

Newsletter

Related Content

How to Responsibly Use AI in Palliative Care and Hematologic Malignancies

A Spatial Atlas of Human Gastrointestinal Acute GVHD Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis

FDA Accepts sBLA for Ropeginterferon in Essential Thrombocytopenia

Tagraxofusp Shows On-Target/Bone Marrow-Sparing Effects in First-Line BPDCN

Latest CME

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Addressing Unmet Needs in HER2+ Metastatic BTC

Trending on CancerNetwork

Phase 2 Trial Will Evaluate CD19 t-haNK Combo in Indolent Lymphomas

Early Time-of-Day Chemoimmunotherapy Boosts Survival in NSCLC

FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC

How Would the Teclistamab Combo Approval Transform Multiple Myeloma?

Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC